MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer (TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but the mechanisms that lead to a therapy resistant tumor immune microenvironment are incompletely known. Here we sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmerli, Dario, Brambillasca, Chiara S., Talens, Francien, Bhin, Jinhyuk, Linstra, Renske, Romanens, Lou, Bhattacharya, Arkajyoti, Joosten, Stacey E. P., Da Silva, Ana Moises, Padrao, Nuno, Wellenstein, Max D., Kersten, Kelly, de Boo, Mart, Roorda, Maurits, Henneman, Linda, de Bruijn, Roebi, Annunziato, Stefano, van der Burg, Eline, Drenth, Anne Paulien, Lutz, Catrin, Endres, Theresa, van de Ven, Marieke, Eilers, Martin, Wessels, Lodewyk, de Visser, Karin E., Zwart, Wilbert, Fehrmann, Rudolf S. N., van Vugt, Marcel A. T. M., Jonkers, Jos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630413/
https://www.ncbi.nlm.nih.gov/pubmed/36323660
http://dx.doi.org/10.1038/s41467-022-34000-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630413/
https://www.ncbi.nlm.nih.gov/pubmed/36323660
http://dx.doi.org/10.1038/s41467-022-34000-6

Ejemplares similares